BMT CTN Protocol 1201 (Alliance A051301)
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype
Below are protocol-related documents, which may be periodically updated.
- Protocol: BMT CTN Protocol 1201 (Alliance A051301)
- This study is posted on clinicaltrials.gov as NCT02443077
- Key Personnel
Protocol Chair: Charalambos Babis Andreadis, MD, MSCE: Charalambos.Andreadis@ucsf.edu
BMT CTN Protocol Chair: Timothy Fenske, MD: tfenske@mcw.edu
Protocol Coordinator: Amy Foley: afoley@nmdp.org
For the Alliance A051301/BMT CTN 1201 study, centers participate via their NCTN group. The protocol may be accessed through the CTSU website: https://www.ctsu.org. For questions, contact the CTSU Help Desk: ctsucontact@westat.com or 1-888-823-5923.